BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Katamura Y, Aikata H, Kimura Y, Kawaoka T, Takaki S, Waki K, Hiramatsu A, Kawakami Y, Takahashi S, Ishikawa M, Hieda M, Kakizawa H, Chayama K. Intra-arterial 5-fluorouracil/interferon combination therapy for hepatocellular carcinoma with portal vein tumor thrombosis and extrahepatic metastases: Chemotherapy for hepatoma. Journal of Gastroenterology and Hepatology 2010;25:1117-22. [DOI: 10.1111/j.1440-1746.2009.06110.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Han KH, Park JY. Systemic treatment in advanced/metastatic hepatocellular carcinoma in the era of targeted therapy. J Gastroenterol Hepatol 2010;25:1023-5. [PMID: 20594213 DOI: 10.1111/j.1440-1746.2010.06359.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
2 Lyu N, Kong Y, Pan T, Mu L, Li S, Liu Y, Deng H, Li J, Shi M, Xu L, Guo R, Chen M, Wu P, Zhao M. Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin in Hepatocellular Cancer with Extrahepatic Spread. J Vasc Interv Radiol 2019;30:349-357.e2. [PMID: 30819477 DOI: 10.1016/j.jvir.2018.09.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
3 Kawaoka T, Aikata H, Kobayashi T, Uchikawa S, Ohya K, Kodama K, Nishida Y, Daijo K, Osawa M, Teraoka Y, Inagaki Y, Honda F, Hatooka M, Morio K, Morio R, Fujino H, Nakahara T, Murakami E, Tsuge M, Hiramatsu A, Imamura M, Kawakami Y, Baba Y, Awai K, Chayama K. Comparison of hepatic arterial infusion chemotherapy between 5-fluorouracil-based continuous infusion chemotherapy and low-dose cisplatin monotherapy for advanced hepatocellular carcinoma. Hepatol Res 2018;48:1118-30. [PMID: 30030881 DOI: 10.1111/hepr.13232] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
4 Masuda K, Ono A, Aikata H, Kawaoka T, Nelson Hayes C, Teraoka Y, Daijo K, Nakamura-inagaki Y, Morio K, Fujino H, Kan H, Uchida T, Masaki K, Kobayashi T, Nakahara T, Makokha GN, Zhang Y, Nagaoki Y, Miki D, Tsuge M, Hiramatsu A, Imamura M, Abe-chayama H, Kawakami Y, Ochi H, Chayama K. Serum HMGB1 concentrations at 4 weeks is a useful predictor of extreme poor prognosis for advanced hepatocellular carcinoma treated with sorafenib and hepatic arterial infusion chemotherapy. J Gastroenterol 2018;53:107-18. [DOI: 10.1007/s00535-017-1348-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
5 Klein J, Dawson LA. Hepatocellular carcinoma radiation therapy: review of evidence and future opportunities. Int J Radiat Oncol Biol Phys. 2013;87:22-32. [PMID: 23219567 DOI: 10.1016/j.ijrobp.2012.08.043] [Cited by in Crossref: 115] [Cited by in F6Publishing: 103] [Article Influence: 11.5] [Reference Citation Analysis]
6 Terashima T, Yamashita T, Arai K, Sunagozaka H, Kitahara M, Nakagawa H, Kagaya T, Mizukoshi E, Honda M, Kaneko S. Feasibility and efficacy of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma after sorafenib. Hepatol Res 2014;44:1179-85. [PMID: 24171787 DOI: 10.1111/hepr.12266] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 3.1] [Reference Citation Analysis]
7 Miyaki D, Aikata H, Honda Y, Naeshiro N, Nakahara T, Tanaka M, Nagaoki Y, Kawaoka T, Takaki S, Waki K. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma according to Child-Pugh classification. J Gastroenterol Hepatol. 2012;27:1850-1857. [PMID: 23020312 DOI: 10.1111/j.1440-1746.2012.07276.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 3.4] [Reference Citation Analysis]
8 Kawaoka T, Aikata H, Hyogo H, Morio R, Morio K, Hatooka M, Fukuhara T, Kobayashi T, Naeshiro N, Miyaki D. Comparison of hepatic arterial infusion chemotherapy versus sorafenib monotherapy in patients with advanced hepatocellular carcinoma. J Dig Dis. 2015;16:505-512. [PMID: 26121102 DOI: 10.1111/1751-2980.12267] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 4.0] [Reference Citation Analysis]
9 Ye HH, Ye JZ, Xie ZB, Peng YC, Chen J, Ma L, Bai T, Chen JZ, Lu Z, Qin HG, Xiang BD, Li LQ. Comprehensive treatments for hepatocellular carcinoma with tumor thrombus in major portal vein. World J Gastroenterol 2016; 22(13): 3632-3643 [PMID: 27053855 DOI: 10.3748/wjg.v22.i13.3632] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
10 Zhang ZM, Guo JX, Zhang ZC, Jiang N, Zhang ZY, Pan LJ. Therapeutic options for intermediate-advanced hepatocellular carcinoma. World J Gastroenterol 2011;17:1685-9. [PMID: 21483627 DOI: 10.3748/wjg.v17.i13.1685] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 29] [Article Influence: 2.3] [Reference Citation Analysis]
11 Hatooka M, Kawaoka T, Aikata H, Inagaki Y, Morio K, Nakahara T, Murakami E, Tsuge M, Hiramatsu A, Imamura M, Kawakami Y, Awai K, Masaki K, Waki K, Kohno H, Kohno H, Moriya T, Nagaoki Y, Tamura T, Amano H, Katamura Y, Chayama K. Hepatic arterial infusion chemotherapy followed by sorafenib in patients with advanced hepatocellular carcinoma (HICS 55): an open label, non-comparative, phase II trial. BMC Cancer 2018;18:633. [PMID: 29866075 DOI: 10.1186/s12885-018-4519-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
12 Ochiai T, Ikoma H, Okamoto K, Kokuba Y, Sonoyama T, Otsuji E. Clinicopathologic features and risk factors for extrahepatic recurrences of hepatocellular carcinoma after curative resection. World J Surg. 2012;36:136-143. [PMID: 22051887 DOI: 10.1007/s00268-011-1317-y] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 2.0] [Reference Citation Analysis]
13 Kodama K, Kawaoka T, Aikata H, Uchikawa S, Inagaki Y, Hatooka M, Morio K, Nakahara T, Murakami E, Tsuge M, Hiramatsu A, Imamura M, Kawakami Y, Masaki K, Honda Y, Mori N, Takaki S, Tsuji K, Kohno H, Kohno H, Moriya T, Nonaka M, Hyogo H, Aisaka Y, Chayama K. Comparison of clinical outcome of hepatic arterial infusion chemotherapy and sorafenib for advanced hepatocellular carcinoma according to macrovascular invasion and transcatheter arterial chemoembolization refractory status. J Gastroenterol Hepatol. 2018;33:1780-1786. [PMID: 29645345 DOI: 10.1111/jgh.14152] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
14 Kawaoka T, Aikata H, Kan H, Fujino H, Fukuhara T, Kobayashi T, Naeshiro N, Miyaki D, Hiramatsu A, Imamura M, Kawakami Y, Hyogo H, Chayama K. Clinical outcome and prognostic factors of patients with hepatocellular carcinoma and extrahepatic metastasis treated with sorafenib: Sorafenib for HCC with extrahepatic metastasis. Hepatol Res 2014;44:1320-8. [DOI: 10.1111/hepr.12307] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
15 Zhao YN, Zhang YQ, Ye JZ, Liu X, Yang HZ, Cong FY, Xiang BD, Wu FX, Ma L, Li LQ, Ye HH. Hepatic resection versus transarterial chemoembolization for patients with Barcelona Clinic Liver Cancer intermediate stage Child-Pugh A hepatocellular carcinoma. Exp Ther Med 2016;12:3813-9. [PMID: 28105115 DOI: 10.3892/etm.2016.3810] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]